leisure time -WSS

leisure time

author：comprehensive 2025-10-01 17:20:57 - browse：9675

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： 15 die by electrocution after transformer explodes in northern India

leisure time

Wikipedia

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

A deep dive into Applied Therapeutics’ data, and questions on Cassava

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Change Healthcare cyberattack prompts Medicare loan program

focus

leisure time

leisure time

The high cost of giving birth even with insurance

Amylyx ALS drug failure raises questions and concerns

After affirmative action ruling, medical educators look to 'holistic review'

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Medicare details structure of new drug price negotiation program

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Cancer drug shortages should be causing more outrage

UnitedHealth quietly bought dozens of outpatient centers

Hollywood unions extend contract negotiations for actors

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

knowledge

A strong 6.5

ER docs worry over extreme heat as a 'mass casualty event'

Biden administration sends mixed signals on US soldier who crossed into North Korea

Twill hunts for pharma partner to market its depression app

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Former medical device CEO who sold dummy, plastic parts convicted of fraud

explore

leisure time

Wikipedia

focus